Preclinical characterization of mobocertinib highlights the putative therapeutic window of this novel EGFR inhibitor to EGFR exon 20 insertion mutations
P. E. N. S. Vasconcelos, I. S. Kobayashi, S. S. Kobayashi, D. B. Costa
This paper characterizes mobocertinib's preclinical efficacy against EGFR exon 20 insertion mutations and identifies EGFR-C797S as a resistance mechanism.
bioRxiv · Sep 28, 2020Cancer Biology